{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:35:02Z","timestamp":1789731302219,"version":"4.0.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fund for Clinical Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Interventions designed to limit the spread of coronavirus disease 2019 (COVID-19) are having profound effects on the delivery of health care, but data showing the impact on oncology clinical trial enrollment, treatment, and monitoring are limited. We prospectively tracked relevant data from oncology clinical trials at Dana-Farber Cancer Institute from January 1, 2018, to June 30, 2020, including the number of open trials, new patient enrollments, in-person and virtual patient visits, dispensed investigational infusions, dispensed or shipped oral investigational agents, research biopsies, and blood samples. We ascertained why patients came off trials and determined on-site clinical research staffing levels. We used 2-sided Wilcoxon rank sum tests to assess the statistical significance of the reported changes. Nearly all patients on interventional treatment trials were maintained, and new enrollments continued at just under one-half the prepandemic rate. The median number of investigational prescriptions shipped to patients increased from 0 to 74 (range = 22-107) per week from March to June 2020. The median number of telemedicine appointments increased from 0 to 107 (range = 33-267) per week from March to June 2020. Research biopsies and blood collections decreased dramatically after Dana-Farber Cancer Institute implemented COVID-19\u2013related policies in March 2020. The number of research nurses and clinical research coordinators on site also decreased after March 2020. Substantial changes were required to safely continue clinical research during the pandemic, yet we observed no increases in serious adverse events or major violations related to drug dosing. Lessons learned from adapting research practices during COVID-19 can inform industry sponsors and governmental agencies to consider altering practices to increase operational efficiency and convenience for patients.<\/jats:p>","DOI":"10.1093\/jnci\/djaa144","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T19:11:08Z","timestamp":1599592268000},"page":"1453-1459","source":"Crossref","is-referenced-by-count":36,"title":["The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute"],"prefix":"10.1093","volume":"113","author":[{"given":"Sara M","family":"Tolaney","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Lydon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Dai","sequence":"additional","affiliation":[{"name":"Pharmacy and Clinical Support, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Standring","sequence":"additional","affiliation":[{"name":"Pharmacy and Clinical Support, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-4431","authenticated-orcid":false,"given":"Kristen A","family":"Legor","sequence":"additional","affiliation":[{"name":"Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn M","family":"Caparrotta","sequence":"additional","affiliation":[{"name":"Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-3890","authenticated-orcid":false,"given":"Matthew P","family":"Schenker","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-5215","authenticated-orcid":false,"given":"Daniel I","family":"Glazer","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"DuBois","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-0898","authenticated-orcid":false,"given":"Jeffrey A","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"issue":"8","key":"2021110218560647500_djaa144-B1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2021110218560647500_djaa144-B2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"issue":"7798","key":"2021110218560647500_djaa144-B3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"10","key":"2021110218560647500_djaa144-B4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"2021110218560647500_djaa144-B5"},{"key":"2021110218560647500_djaa144-B6"},{"issue":"20","key":"2021110218560647500_djaa144-B7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2020.6236","article-title":"Oncology practice during the COVID-19 pandemic","volume":"323","author":"Schrag","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"2021110218560647500_djaa144-B8","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.20.00960","article-title":"Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic","volume":"38","author":"Marron","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021110218560647500_djaa144-B9"},{"key":"2021110218560647500_djaa144-B10"},{"key":"2021110218560647500_djaa144-B11"},{"key":"2021110218560647500_djaa144-B12"},{"key":"2021110218560647500_djaa144-B13"},{"issue":"6","key":"2021110218560647500_djaa144-B14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41571-020-0370-6","article-title":"Provision of cancer care during the COVID-19 pandemic","volume":"17","author":"Spicer","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2021110218560647500_djaa144-B15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021110218560647500_djaa144-B16","first-page":"417","article-title":"Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey","volume":"16","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol Pract"},{"key":"2021110218560647500_djaa144-B17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaoncol.2020.3142","article-title":"Rethinking clinical trials reform during the COVID-19 pandemic","author":"Nabhan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"2021110218560647500_djaa144-B18","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1200\/JCO.2005.03.8976","article-title":"Factors associated with participation in breast cancer treatment clinical trials","volume":"24","author":"Avis","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021110218560647500_djaa144-B19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/theoncologist.2015-0481","article-title":"Financial burden of cancer clinical trial participation and the impact of a cancer care equity program","volume":"21","author":"Nipp","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"2021110218560647500_djaa144-B20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"issue":"39","key":"2021110218560647500_djaa144-B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaa144\/34286706\/djaa144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/113\/11\/1453\/41053972\/djaa144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/113\/11\/1453\/41053972\/djaa144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T21:39:47Z","timestamp":1635889187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/113\/11\/1453\/5906529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaa144","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,9,22]]}}}